NCT00052832已完成2 期
Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia.
PURPOSE: Phase II trial to study the effectiveness of doxercalciferol in treating patients who have myelodysplastic syndrome or chronic myelomonocytic leukemia.
详细描述
OBJECTIVES:
- Determine the response rate of patients with myelodysplastic syndromes or chronic myelomonocytic leukemia treated with doxercalciferol.
- Determine the toxicity profile of this drug in these patients.
- Determine the time to progression and overall survival of patients treated with this drug.
OUTLINE: Patients receive oral doxercalciferol daily for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: Approximately 41 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Morphologically and cytogenetically confirmed myelodysplastic syndromes or chronic myelomonocytic leukemia
- •No more than 20% blasts by bone marrow biopsy
- •Must meet at least 1 of the following criteria:
- •Hemoglobin less than 11 g/dL over a 2-month period
- •Thrombocytopenia
- •Neutropenia
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •Not specified
- •Hematopoietic
- •See Disease Characteristics
- •ALT and AST less than 1.5 times upper limit of normal
- •Bilirubin less than 3 mg/dL
- •Albumin greater than 3.0 g/dL
- •Creatinine clearance greater than 50 mL/min
- •No history of hypercalcemia
- •No renal stones within the past 5 years
- •Cardiovascular
- •No clinically significant heart failure
- •No uncontrolled hypertension
- •No clinically significant pulmonary failure
- •Not pregnant
- •Fertile patients must use effective contraception during and for 6 months after study
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •At least 4 weeks since prior growth factor or cytokine therapy
- •Chemotherapy
- •At least 8 weeks since prior cytotoxic chemotherapy
- •Endocrine therapy
- •Not specified
- •Radiotherapy
- •Not specified
- •Not specified
- •Concurrent transfusion support allowed
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate CancerProstate CancerNCT00582582University of Wisconsin, Madison70
终止
1 期
Doxercalciferol in Recurrent Pediatric Solid TumorsSolid TumorsNCT00511017M.D. Anderson Cancer Center1
已完成
4 期
Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis PatientsVitamin D DeficiencyBone Diseases, MetabolicKidney Failure, ChronicAnemiaNCT02214563Takayuki Hamano90
已完成
2 期
Cholecalciferol in Treating Patients With Myelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmsMyelodysplastic SyndromesLeukemiaNCT00068276Wake Forest University Health Sciences
终止
2 期
Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency.Critical IllnessVitamin D DeficiencyNCT02868827King Abdullah Medical City127